ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Lazard Capital Markets Healthcare Conference in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s oncology pipeline on Tuesday, November 15 at 1:00 p.m. (ET). Dr. Berger also will discuss the early interim safety and efficacy results from the pivotal PACE trial of ponatinib, ARIAD’s investigational pan-BCR-ABL inhibitor, that were published earlier this week in an abstract for presentation at the upcoming annual meeting of the American Society of Hematology being held next month.
